the aid library

LIST OPTIONS

Filter

9133

Download (1132)

View PDF (1706)

Implementation of Option B+ for prevention of Mother-To-Child Transmission of HIV: The Malawi Experience

World Health Organization; Regional Office for Africa (2014) C_WHO

Download (1019)

View PDF (3645)

National strategy and plan of action for pharmaceutical manufacturing development in Ethiopia (2015–2025)

Ministry of Health and Ministry of Industry, Federal Democratic Republic of Ethiopia (2015) C1

Strategy plan

Download (301)

View PDF (316)

Conducting HIV surveillance based on routine programme data among pregnant women attending antenatal clinics

J. M. Garcia Calleja; J. Dee; L. Newman; et al. World Health Organization; UNAIDS (2015) C_WHO

Guidelines UNAIDS/WHO working group on global HIV/AIDS and STI surveillance August 2015 HIV strategic information for impact

Download (390)

View PDF (800)

World Report of Disability - Summary

World Health Organization (WHO) & The World Bank (WB) (2011) C_WHO

Download (688)

View PDF (958)

Screening donated blood for transfusion-transmissible infections: recommendations

World Health Organization (WHO) (2009) C_WHO

The provision of safe and efficacious blood and blood components for transfusion or manufacturing use involves a number of processes, from the selection of blood donors and the collection, processing and testing of blood donations to the testing of patient samples, the issue of compatible blood and ... more

Download (676)

View PDF (1554)

Implementation manual to support the prevention of surgical site infections at the facility level: turning recommendations into practice
recommended

World Health Organization WHO (2020) C_WHO

Download (375)

View PDF (518)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

Download (294)

View PDF (432)

Point-of-care tests for sexually transmitted infections: target product profiles

World Health Organisation (WHO) (2023) C_WHO

Despite the development of point-of-care diagnostic tests for syphilis, chlamydia, gonorrhoea, and trichomoniasis, none comply with all WHO criteria. This analysis overviews landscape analyses of point-of-care diagnostic technologies for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vagi... more

Download (419)

View PDF (683)

Iodine thyroid blocking Guidelines for use in planning for and responding to radiological and nuclear emergencies

World Health Organization (WHO) (2017) C_WHO

These guidelines provide a recommendation on iodine thyroid blocking (ITB), via oral administration of stable iodine, as an urgent protective action in responding to a nuclear accident. This recommendation aims to support emergency planners, policy makers, public health specialists, clinicians and o... more

Download (329)

View PDF (325)

Report of the fourth WHO stakeholders meeting on gambiense and rhodesiense human African trypanosomiasis elimination: virtual meeting, 1–3 June 2021

World Health Organization WHO (2021) C_WHO

Since 2000, concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypan... more

Download (365)

View PDF (521)

Interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions

World Health Organization WHO (2019) C_WHO

An interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions was organized by the World Health Organization (WHO) Regional Office for the Eastern Mediterranean in Amman, Jordan, from 23 to 25 September 2018. The meeting w... more

Download (349)

View PDF (454)

Patient safety assessment manual
recommended

World Health Organization WHO (2022) C_WHO

3rd edition. Patient safety standards are critical for the establishment and assessment of patient safety programmes within hospitals. This third edition of the Patient safety assessment manual provides an updated set of standards and assessment criteria that reflect current best practice and WHO gu... more

Download (325)

View PDF (498)

Strategic framework for collaboration on antimicrobial resistance

World Health Organization WHO (2022) C_WHO

Together for One Health. Building on the momentum of increased collaboration, the WHO, FAO, OIE and UNEP have developed a Strategic Framework for collaboration on antimicrobial resistance (AMR). This Framework reflects the joint work of the four organizations to advance a One Health response to AMR ... more

Download (418)

View PDF (257)

Barbados National Action Plan on Combatting Antimicrobial Resistance 2017-2022

MINISTRY OF HEALTH, BARBADOS (2017) C_WHO

Barbados currently has a rudimentary framework and capacity to address the issue of antimicrobial resistance. There however needs to be coordination of efforts and improvement in areas where gaps have been identified.Actions required include improved antibiotic stewardship in healthcare settings, pr... more

Download (274)

View PDF (572)

HIV prevention 2025 road map

UNAIDS World Health Organization WHO (2022) C_WHO

Getting on track to end AIDS as a public health threat by 2030. This new Road Map charts a way forward for country-level actions to achieve an ambitious set of HIV prevention targets by 2025. Those targets emerged from the 2021 Political Declaration on HIV and AIDS, which the United Nations General ... more

Download (1326)

View PDF (3385)

Oral Cholera Vaccine Use in Complex Emergencies: What next?

World Health Organization (2005)

Download (403)

View PDF (651)

Strategy and plan of action on epilepsy

Pan American Health Organisation (PAHO) World Health Organization (WHO) (2011) C_WHO

Epilepsy is one of the world’s most common chronic neurological disorders. Roughly 50 million people suffer from it, 5 million of them in the Region of the Americas . Nevertheless, it is estimated that over 50% of these people in Latin America and the Caribbean have no access to services. Furthe... more

Download (341)

View PDF (479)

Assist - The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

R. Humeniuk, S. Henry-Edwards, R. Ali; et al. World Health Organization WHO (2010) C_WHO

Manual for use in primary care. There is substantial evidence for the benefits of screening and brief intervention in primary health care for alcohol problems. However, there is a need for screening and brief interventions with cross-cultural relevance for substances other than alcohol or tobacco,... more

Download (344)

View PDF (346)

Transgender people and HIV

D. Adams; J. Byrne; M. Cabra; et al. World Health Organization (2015) C_WHO

Policy Brief

Download (470)

View PDF (696)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Implementation manual to support the prevention of surgical site infections at the facility level: turning recommendations into practice recommended

Patient safety assessment manual recommended

Implementation manual to support the prevention of surgical site infections at the facility level: turning recommendations into practice
recommended

Patient safety assessment manual
recommended